Haemonetics Co. (NYSE:HAE) Short Interest Update

Haemonetics Co. (NYSE:HAE) was the target of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 6,830,000 shares, an increase of 30.3% from the January 31st total of 5,240,000 shares. Based on an average daily trading volume, of 792,300 shares, the short-interest ratio is presently 8.6 days. Currently, 13.8% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Vise Technologies Inc. boosted its stake in shares of Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier’s stock worth $221,000 after buying an additional 225 shares during the last quarter. Waverly Advisors LLC raised its holdings in Haemonetics by 17.0% during the fourth quarter. Waverly Advisors LLC now owns 12,769 shares of the medical instruments supplier’s stock worth $997,000 after acquiring an additional 1,857 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its position in Haemonetics by 31.0% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 643,227 shares of the medical instruments supplier’s stock valued at $50,223,000 after purchasing an additional 152,042 shares during the last quarter. ProShare Advisors LLC grew its stake in Haemonetics by 40.7% in the fourth quarter. ProShare Advisors LLC now owns 16,486 shares of the medical instruments supplier’s stock valued at $1,287,000 after purchasing an additional 4,771 shares in the last quarter. Finally, Nomura Holdings Inc. acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $519,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Up 1.4 %

HAE traded up $0.92 during trading on Thursday, hitting $68.08. The company had a trading volume of 64,723 shares, compared to its average volume of 1,005,982. The company has a market capitalization of $3.42 billion, a PE ratio of 26.77, a PEG ratio of 1.11 and a beta of 0.39. The firm’s 50-day moving average price is $70.18 and its 200 day moving average price is $75.83. Haemonetics has a one year low of $58.80 and a one year high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, equities analysts expect that Haemonetics will post 4.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on HAE shares. JMP Securities lowered their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a report on Friday, February 7th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Barrington Research cut their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC reduced their target price on Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Raymond James reiterated a “strong-buy” rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.